Bora Pharmaceuticals Co., Ltd. yesterday (April 1) finalized the acquisition of Upsher-Smith Laboratories, Inc., a leading generics manufacturer based in Minnesota, U.S., from its previous owners, Sawai Group Holdings and Sumitomo Corporation of Americas.
Life sciences investment group and part of global investment firm Carlyle, Abingworth announced last week it had exceeded its $300 million target by $56 million.
A transaction between Citius Pharmaceuticals and TenX Keane which will result in the formation of Citius Oncology, Inc. is due to close in the first half of next year (2024).
Danaher is to acquire Abcam for $24 per share - a total enterprise value of approximately $5.7 billion representing approximately 40% more than Abcam's undisclosed share prices in May.
The US drug developer Nanopharmaceutics has teamed up with PrecisionLife in a strategic collaboration to accelerate the development of Nanopharmaceutics’ central nervous system (CNS) drug pipeline with precision medicine.
The Japanese company Shionogi has taken over the US biotech Qpex Biopharma for up to $140 million in a bid to expand its pipeline of antimicrobial drugs and boost its R&D muscle in infectious disease.
After completing the acquisition of Aveo, the Korean chemical company wants its subsidiary to become a global leader in the therapeutic area within five years.
Charité – Universitätsmedizin Berlin, one of Europe’s largest university hospitals is collaborating with UK-based Exscientia to make use of an artificial intelligence-driven precision medicine platform in haematological cancers.
The two companies announce a business combination via a proposed all share merger transaction, effectively combining the pipelines and workforce of the two biotechs.
With the purchase, the company is looking to advance its plans to connect with potential trial participants and spread awareness of study participation.
This month’s announcements of appointments, acquisitions, new hires, and other news include Standigm, Astellas Pharma, Trialbee, and other key companies.
The pharmaceutical company has completed acquisition of Turning Point Therapeutics, a company specializing in precision medicine solutions for cancer patients.
The purchase brings under the UPS Healthcare umbrella several temperature-controlled facilities in 14 countries situated throughout Europe and Latin America.
Biopharmaceutical company Global Blood Therapeutics specializes in conditions that often disproportionately impact underrepresented communities, such as SCD.
This month’s announcements of appointments, partnerships, expansions, and mergers include Curia, Thread, TFF Pharmaceuticals, and other notable companies.
This month’s announcements of launches, appointments, and partnerships includes Saama, COTA, Yourway, Eversana, Kindeva, and other notable industry companies.
This month’s announcements of awards, investments, executive appointment, and expansions include Javara, Thread, uMotif, Lonza, and other notable companies.
This month’s news on partnerships, appointments, expansions, and investment includes Javara, ACG, Phastar, Elligo Health Research, and other notable companies.
The company’s recent purchase by Drug Safety and Pharmacovigilance Services Solutions reportedly will fuel expansion of its Reportum PV platform technology.
This month’s news includes hiring, promotions, expansions, and acquisitions at H Clinical, Charles River, DHL Supply Chain, X-Chem, and other key companies.
The union of the active pharmaceutical ingredient supplier and contract development and manufacturing organization will create a global services company.
This month’s announcements include hiring, expansion, and acquisition news from companies like DFE Pharma, ClinOne, Novartis, LEGO, Benchling, and more.
This month’s announcements include new hires, promotions, acquisitions, and other events from Saama, Javara, Firma, GlaxoSmithKline, and other companies.
This month’s list of new technology, partnerships, and other announcements includes items from ObvioHealth, Datavant, HumanFirst, and other industry players.
This month’s news on mergers and acquisitions, hires, and other developments includes notable firms like Altasciences, Protocol First, WuXi STA, and more.
OSP’s list of the year’s most-read stories shows readers are interested in M&A activities, new drug candidates, COVID-19 developments, and other hot news.
The pharmaceutical company currently has several promising treatments in development for gastroenterological, dermatological, and cardiological conditions.
The alliance is aimed at expanding service to pharmaceutical firms and other partners, and advancing treatment options for patients across North America.
The decentralized tech specialist has acquired Digital Artefacts, a research tech firm focused on cognitive, behavioral, and physiological data capture.
This month’s announcements of programs, names, appointments, hires, and other happenings includes items from Emmes, Science 37, Cerner and other companies.
The US-based company continues its move away from smoking products with the purchase of drug developer OtiTopic, as part of its Beyond Nicotine initiative.
This month’s news on hires, promotions, acquisitions, expansions, and funding includes items about Syneos Health, ProSciento, Phastar, CPhI, Immunai, and other key industry players.
An expert speaking during the industry event offers insight and perspective on the flurry of CDMO deal-making in recent months, and what might lie ahead.
The past several days have seen a relatively large number of industry acqusitions, with Lilly, Phillip Morris, WCG, CTI and others making notable buys.
This month’s news on hires, promotions, acquisitions, and expansions includes items about Javara, Elligo, Lonza, Yourway, Medable, and other notable firms.
As the industry begins coming out of the COVID-19 pandemic, experts advise keeping an eye on growth and partnership opportunities in the US pharma market.
This month’s roundup of hires, acquisitions, anniversaries, and other announcements includes news from Premier Research, Cytel, ACG, and other companies.
The newly formed company (valued at $1.05b USD) will center on funding the firm’s decentralized trial technology platform and exploring new opportunities,
The chairman, president and CEO of Thermo Fisher says the acquisition stands to benefit clinical trial and drug development clients in a long list of ways.
The science service and technologies firm plans to bring the CRO under its Laboratory Products and Services Segment umbrella after the deal is completed.
The clinical research tech specialists, which had held 60% of Q2 Diagnostics, will now wholly own the comprehensive clinical laboratory services company.
